Literature DB >> 32255276

Advances in engineering local drug delivery systems for cancer immunotherapy.

Peter Abdou1,2, Zejun Wang1,2, Qian Chen3, Amanda Chan1,2, Daojia R Zhou1,2, Vivienne Gunadhi1, Zhen Gu1,2.   

Abstract

Cancer immunotherapy aims to leverage the immune system to suppress the growth of tumors and to inhibit metastasis. The recent promising clinical outcomes associated with cancer immunotherapy have prompted research and development efforts towards enhancing the efficacy of immune checkpoint blockade, cancer vaccines, cytokine therapy, and adoptive T cell therapy. Advancements in biomaterials, nanomedicine, and micro-/nano-technology have facilitated the development of enhanced local delivery systems for cancer immunotherapy, which can enhance treatment efficacy while minimizing toxicity. Furthermore, locally administered cancer therapies that combine immunotherapy with chemotherapy, radiotherapy, or phototherapy have the potential to achieve synergistic antitumor effects. Herein, the latest studies on local delivery systems for cancer immunotherapy are surveyed, with an emphasis on the therapeutic benefits associated with the design of biomaterials and nanomedicines. This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  biomaterials; drug delivery; immunotherapy; local delivery; nanomedicine

Mesh:

Substances:

Year:  2020        PMID: 32255276      PMCID: PMC7725287          DOI: 10.1002/wnan.1632

Source DB:  PubMed          Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol        ISSN: 1939-0041


  278 in total

1.  In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment.

Authors:  Qian Chen; Chao Wang; Xudong Zhang; Guojun Chen; Quanyin Hu; Hongjun Li; Jinqiang Wang; Di Wen; Yuqi Zhang; Yifei Lu; Guang Yang; Chen Jiang; Jun Wang; Gianpietro Dotti; Zhen Gu
Journal:  Nat Nanotechnol       Date:  2018-12-10       Impact factor: 39.213

Review 2.  Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists.

Authors:  Gregory L Beatty; Yan Li; Kristen B Long
Journal:  Expert Rev Anticancer Ther       Date:  2016-12-14       Impact factor: 4.512

Review 3.  IL-2: the first effective immunotherapy for human cancer.

Authors:  Steven A Rosenberg
Journal:  J Immunol       Date:  2014-06-15       Impact factor: 5.422

4.  Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events.

Authors:  Jun Ishihara; Kazuto Fukunaga; Ako Ishihara; Hans M Larsson; Lambert Potin; Peyman Hosseinchi; Gabriele Galliverti; Melody A Swartz; Jeffrey A Hubbell
Journal:  Sci Transl Med       Date:  2017-11-08       Impact factor: 17.956

Review 5.  Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook.

Authors:  Chao Wang; Yanqi Ye; Quanyin Hu; Adriano Bellotti; Zhen Gu
Journal:  Adv Mater       Date:  2017-05-26       Impact factor: 30.849

6.  MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation.

Authors:  Praveen K Bommareddy; Salvatore Aspromonte; Andrew Zloza; Samuel D Rabkin; Howard L Kaufman
Journal:  Sci Transl Med       Date:  2018-12-12       Impact factor: 17.956

Review 7.  Immunotherapy of cancers comes of age.

Authors:  Hila Yousefi; Jianda Yuan; Mahsa Keshavarz-Fathi; Joseph F Murphy; Nima Rezaei
Journal:  Expert Rev Clin Immunol       Date:  2017-08-23       Impact factor: 4.473

8.  Cowpea Mosaic Virus Nanoparticles and Empty Virus-Like Particles Show Distinct but Overlapping Immunostimulatory Properties.

Authors:  Chao Wang; Veronique Beiss; Nicole F Steinmetz
Journal:  J Virol       Date:  2019-10-15       Impact factor: 5.103

9.  Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism.

Authors:  Galina V Shurin; Irina L Tourkova; Ramon Kaneno; Michael R Shurin
Journal:  J Immunol       Date:  2009-06-17       Impact factor: 5.422

Review 10.  Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances.

Authors:  Guy R Simpson; Kate Relph; Kevin Harrington; Alan Melcher; Hardev Pandha
Journal:  Oncolytic Virother       Date:  2016-01-06
View more
  5 in total

Review 1.  Design of Bio-Conjugated Hydrogels for Regenerative Medicine Applications: From Polymer Scaffold to Biomolecule Choice.

Authors:  Vittoria Chimisso; Miguel Angel Aleman Garcia; Saziye Yorulmaz Avsar; Ionel Adrian Dinu; Cornelia G Palivan
Journal:  Molecules       Date:  2020-09-07       Impact factor: 4.411

Review 2.  Immunology Meets Bioengineering: Improving the Effectiveness of Glioblastoma Immunotherapy.

Authors:  Zahra Fekrirad; Amir Barzegar Behrooz; Shokoofeh Ghaemi; Arezou Khosrojerdi; Atefeh Zarepour; Ali Zarrabi; Ehsan Arefian; Saeid Ghavami
Journal:  Cancers (Basel)       Date:  2022-07-29       Impact factor: 6.575

Review 3.  Nanomedicine approaches for treatment of hematologic and oncologic malignancies.

Authors:  Polyxeni Nteli; Danae Efremia Bajwa; Dimitrios Politakis; Charalampos Michalopoulos; Anastasia Kefala-Narin; Efstathios P Efstathopoulos; Maria Gazouli
Journal:  World J Clin Oncol       Date:  2022-07-24

Review 4.  Mesoporous Silica Materials as an Emerging Tool for Cancer Immunotherapy.

Authors:  Blanca Escriche-Navarro; Andrea Escudero; Elena Lucena-Sánchez; Félix Sancenón; Alba García-Fernández; Ramón Martínez-Máñez
Journal:  Adv Sci (Weinh)       Date:  2022-07-22       Impact factor: 17.521

5.  Nanoscale metal-organic frameworks for x-ray activated in situ cancer vaccination.

Authors:  Kaiyuan Ni; Guangxu Lan; Nining Guo; August Culbert; Taokun Luo; Tong Wu; Ralph R Weichselbaum; Wenbin Lin
Journal:  Sci Adv       Date:  2020-10-02       Impact factor: 14.136

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.